Healthy Volunteers
Conditions
Keywords
MRM-3379, [14C]-MRM-3379, Mass balance, ADME
Brief summary
This is a Phase 1, open label study in healthy male participants to study the Absorption, Distribution, Metabolism, and Excretion of \[14C\]-MRM-3379 drug following a single oral dose.
Interventions
DRUG[14C]-MRM-3379
Oral capsule administered on Day 1 only.
Sponsors
Mirum Pharmaceuticals, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male of any race, between 18 and 55 years of age, inclusive. 2. Body mass index between 18.0 and 32.0 kg/m2, inclusive, and a body weight between 50 and 110 kg, inclusive. 3. In good health, as determined by medical history, and as assessed by the investigator (or designee). 4. Able to comprehend and are willing to sign the ICF and abide by the trial restrictions.
Exclusion criteria
1. History of or current medical condition that would place the participant at risk from study participation. 2. Administration of any vaccine within 30 days prior to dosing. 3. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, considered to potentially impact participant safety or the objectives of the trial, as determined by the investigator (or designee). 4. Participation in a clinical trial involving administration of an IMP (new chemical entity) in the past 30 days or 5 half-lives of that drug (if known) prior to dosing, whichever is longer. 5. Have previously completed or withdrawn from this trial or any other trial investigating MRM-3379 or have previously received MRM-3379. 6. Participants who have previously been dosed in \>2 radiolabeled drug studies in the last 12 months. For participants who have previously been dosed in ≤2 radiolabeled drug studies within the last 12 months, the previous radiolabeled dose must be at least 4 months prior to check-in to the trial site where exposures are known to the investigator or 6 months prior to check-in to the trial site for a radiolabeled drug trial where exposures are not known to the investigator. The total 12-month exposure from this trial and a maximum of 2 other previous radiolabeled studies must be within the CFR recommended levels considered safe, per US Title 21 CFR 361.1. 7. Participants with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in. 8. Participants who, in the opinion of the investigator (or designee), should not participate in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total radioactivity recovery of MRM-3379 in urine and feces | Up to 11 days post dose | Evaluate the cumulative and total radioactivity in urine and feces following administration of a single oral dose of radiolabeled MRM-3379. |
| Maximum observed concentration (Cmax) of MRM-3379 and 2 metabolites in plasma | Up to 11 days post dose | — |
| Time to maximum observed concentration (tmax) of MRM-3379 and 2 metabolites in plasma | up to 11 days post dose | — |
| Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-tlast) of MRM-3379 and 2 metabolites in plasma | up to 11 days post dose | — |
| Maximum observed concentration (Cmax) of total radioactivity in plasma and whole blood | up to 11 days post dose | — |
| Time to maximum observed concentration (tmax) of total radioactivity in plasma and whole blood | up to 11 days post dose | — |
| Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-tlast) of total radioactivity in plasma and whole blood | Up to 11 days post dose | — |
| Amount of MRM-3379 and 2 metabolites excreted in the urine (Ae) over sampling period | Up to 11 days post dose | — |
| Fraction of MRM-3379 and 2 metabolites excreted in the urine (Fe) as Ae/dose | Up to 11 days post dose | — |
| Renal clearance of MRM-3379 as Ae/AUC | Up to 11 days post dose | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of metabolites in plasma and excreta by liquid chromatography-radiochemical-detection and subsequent mass spectrometry | Up to 11 days post dose | Evaluate the quantitative metabolic profile of MRM-3379 in plasma, urine, and feces via radiochromatographic profiles and identify associated metabolites following administration of a single oral dose of radiolabeled MRM-3379. |
| Number of subjects with treatment-related adverse events | Up to 11 days post dose | — |
Countries
United States
Contacts
CONTACTClinical Trials Mirum
CONTACTMedinfo Mirum
PRINCIPAL_INVESTIGATORKimberly Cruz, MD
Fortrea Clinical Research Unit Inc.
Outcome results
None listed